| Detailed information |
|---|
| CancerLivER ID | 2237 |
| Biomarker | ANRIL |
| Biomarker Name/Symbol (given in Publication) | ANRIL |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | ANRIL, as a growth regulator, may serve as a new biomarker and target for therapy in HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC with Fold change >1.0 |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 25966845 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | 77 fresh HCC tissue samples and matched normal adjacent tissue samples; Human HCC cell lines (HepG2, Hep3B, MHCC-97H) and one normal hepatic epithelial cell line (L02, control) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |